Wall Street analysts’ outlook for YS Biopharma Co. Ltd. (YS)

YS Biopharma Co. Ltd. (NASDAQ: YS) stock fell -0.41% on Friday to $0.90 against a previous-day closing price of $0.90. With 2.76 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.95 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0800 whereas the lowest price it dropped to was $0.8600. The 52-week range on YS shows that it touched its highest point at $18.44 and its lowest point at $0.75 during that stretch. It currently has a 1-year price target of $5.10. Beta for the stock currently stands at -0.36.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of YS was down-trending over the past week, with a drop of -10.89%, but this was down by -18.18% over a month. Three-month performance dropped to -34.78% while six-month performance fell -93.08%. The stock lost -90.76% in the past year, while it has lost -91.02% so far this year. A look at the trailing 12-month EPS for YS yields 0.69 with Next year EPS estimates of -0.33.

Float and Shares Shorts:

At present, 93.06 million YS shares are outstanding with a float of 87.31 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.71 million, which was 0.76% higher than short shares on Jul 30, 2023. In addition to Mr. Gang Li as the firm’s Head of Marketing & Sales, Dr. Yuan Liu serves as its Head of Vaccine Research.

Institutional Ownership:

Through their ownership of 13.87% of YS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.02% of YS, in contrast to 2.74% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in YS with 2.92% of the stake, FIL Investment Advisors holds 2,718,499 shares worth 2,718,499. A second-largest stockholder of YS, 3W Fund Management Ltd., holds 2,240,746 shares, controlling over 2.41% of the firm’s shares. Valliance Asset Management Ltd. is the third largest shareholder in YS, holding 1,607,175 shares or 1.73% stake. With a 2.52% stake in YS, the Biotech Growth Trust Plc is the largest stakeholder. A total of 2,347,011 shares are owned by the mutual fund manager. The Lumyna – MW TOPS UCITS Fund, which owns about 0.10% of YS stock, is the second-largest Mutual Fund holder. It holds 93,753 shares valued at 0.11 million. Lumyna – MW Systematic Alpha UCIT holds 0.06% of the stake in YS, owning 56,119 shares worth 66782.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, YS reported revenue of $205.48M and operating income of -$11.74M. The EBITDA in the recently reported quarter was -$11.61M and diluted EPS was -$0.59.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for YS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Leave a Comment

Your email address will not be published. Required fields are marked *